Clinical trials: Alzheimer's Disease in Down Syndrome
Down Syndrome, Alzheimer Disease
Vitamin E in Aging Persons With Down Syndrome
The goal of this study is to determine the safety and efficacy of the administration of vitamin E, which has been shown to delay the progression of Alzheimer's disease, in slowing the rate of cognitive/functional decline in older…
- Trial name
- NCT00056329
- Testing
- Vitamin E, multivitamin
- Where
- 22 sites in United States, Australia and 2 more
- Volunteers
- 350 people
- Sponsor
- New York State Institute for Basic Research
Alzheimer's Disease in Down Syndrome
Down Syndrome Clinical Trials - Study of Alzheimer's Disease in Down Syndrome
The primary objective is to characterize trajectories of change on the primary outcome measures in this study population through longitudinal collection of measures of cognition, function, behavior, and health status.
- Trial name
- LIFE-DSR (NCT04149197)
- Where
- 14 sites in United States
- Volunteers
- 252 people
- Sponsor
- LuMind IDSC Foundation
Amyloid Plaque, Beta-Amyloid
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
- Conditions
- Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease
- Trial name
- NCT05462106
- Testing
- ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a
- Where
- 26 sites in United States, Spain and 1 more
- Volunteers
- 304 people
- Sponsor
- AC Immune SA
Down Syndrome (DS)
Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool
Epigallocatechin-3-gallate (EGCG), the major catechin in green tea, is postulated to modulate dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) and amyloid beta precursor protein (APP) gene overexpression in…
- Trial name
- NCT01699711
- Testing
- Epigallocatechin-3-gallate (EGCG)
- Where
- Spain
- Volunteers
- 87 people
- Sponsor
- Parc de Salut Mar
Down Syndrome
LIFE-DSR-Biomarker Sub-study of Biomarkers in Down Syndrome Related Alzheimer's Disease (DS-AD)
This is an optional sub-study that will enroll participants from the LIFE-DSR parent protocol. Participants will undergo assessments at two timepoints, including: additional blood samples for PBMC and RNA extraction, as well as a…
- Trial name
- NCT06860373
- Testing
- [18F]MK-6240
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- LuMind IDSC Foundation
Alzheimer's Disease, Down Syndrome
Multicenter Vitamin E Trial in Aging Persons With Down Syndrome
The purpose of this study is to determine the safety and effectiveness of 2,000 international units of Vitamin E (alpha tocopherol)on cognitive function of aging persons with Down syndrome.
- Trial name
- NCT01594346
- Testing
- Alpha-Tocopherol, Sugar Pill
- Volunteers
- 349 people
- Sponsor
- New York State Institute for Basic Research
Down Syndrome
Gamma Frequency Stimulation in Individuals With Down Syndrome
Down Syndrome (DS) is characterized by an additional copy of chromosome 21, which also increases risk of Alzheimer's Disease (AD).
- Trial name
- NCT05196984
- Testing
- GENUS device (Active Settings)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Massachusetts Institute of Technology
Down Syndrome, Cognitive Decline
GnRH Therapy on Cognition in Down Syndrome
Down syndrome (DS) is the most common chromosomal disorder; with the increasing life expectancy, about 80% of DS adults reach age 65 years old.
- Conditions
- Down Syndrome, Cognitive Decline, Alzheimer Disease, Early Onset, Olfaction Disorders
- Trial name
- NCT04390646
- Testing
- GnRH, gonadorelin acetate, 0.9% NaCl
- Where
- Switzerland
- Volunteers
- 56 people
- Sponsor
- Nelly Pitteloud
Intellectual Disability, Neurodevelopmental Disorders
Physical Activity and Community EmPOWERment Project
Purpose: Conduct a wait-list randomized controlled trial (RCT) of an inclusive physical activity program called PACE for adults with intellectual disability (ID) who are not yet showing signs of Alzheimer's Disease…
- Conditions
- Intellectual Disability, Neurodevelopmental Disorders, Autism Spectrum Disorder, Down Syndrome
- Trial name
- PACE (NCT06740162)
- Testing
- PACE Program
- Where
- 2 sites in United States
- Volunteers
- 376 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Alzheimer's Disease, Obstructive Sleep Apnea
Sleep in Adults With Down Syndrome and Alzheimer's Disease
RATIONALE of the project. Adults with Down syndrome (DS) present severe sleep disorders that are under recognized by caregivers.
- Conditions
- Alzheimer's Disease, Obstructive Sleep Apnea, Sleep Disturbances
- Trial name
- NCT03942341
- Where
- Spain
- Volunteers
- 90 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Alzheimer Disease, Down Syndrome
Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)
The primary purpose of this study is to evaluate the safety and tolerability of ION269 in adults with Down syndrome with evidence of brain amyloid positivity.
- Trial name
- NCT06673069
- Testing
- ION269
- Where
- 6 sites in United States, Spain
- Volunteers
- 1 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Down Syndrome
Natural History of Amyloid Deposition in Adults With Down Syndrome
The primary objective of this study is to assess the presence of amyloid in non-demented/functionally stable adults with DS as a function of age, dividing the sample into amyloid-positive and amyloid-negative groups.
- Trial name
- NCT01303133
- Where
- 2 sites in United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Down Syndrome-Associated Alzheimer's Disease (DS-AD)
A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
The purpose of the study is to evaluate the effect of mivelsiran in adult participants with early-stage DS-AD and to characterize the safety, tolerability, and pharmacodynamics (PD) of mivelsiran.
- Trial name
- NCT07636811
- Testing
- Mivelsiran
- Where
- 10 sites in United States, Spain
- Volunteers
- 58 people
- Sponsor
- Alnylam Pharmaceuticals
Down Syndrome (DS)
NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome
The aim of the study is to determine the safety and tolerability of different increasing doses of MIB-626 (a microcrystalline form of β nicotinamide mononucleotide; NMN) given daily for 28 consecutive days to adults with Down…
- Trial name
- NCT07278492
- Testing
- MIB-626
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Brigham and Women's Hospital
Down Syndrome, Intellectual Disability
Escalating Doses of Memantine in Down Syndrome (MEDS-123)
Down syndrome (DS) is typically caused by an extra chromosome 21 in the cell nucleus (trisomy 21, or T21). T21 is both the most common cause of genetically defined intellectual disability and the earliest documented cause of…
- Conditions
- Down Syndrome, Intellectual Disability, Alzheimer Dementia (AD)
- Trial name
- NCT07531940
- Testing
- Memantine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University Hospitals Cleveland Medical Center
Healthy Volunteers, Down Syndrome
Leucettinib-21 First-in-Human Phase 1 in Healthy Volunteers and Subjects With Down Syndrome and Alzheimer's Disease
Leucettinib-21 First-in-Human Phase 1 Study in 6 Parts: Single (Part 1 and 5) and Multiple (Part 3 and 6) Ascending Doses, and Food-Effect (Part 2) in Healthy Subjects, and Single Dose (Part 4) in People with Down Syndrome (DS)…
- Conditions
- Healthy Volunteers, Down Syndrome, Alzheimer's Disease
- Trial name
- LEUCETTA (NCT06206824)
- Testing
- Leucettinib-21
- Where
- France
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Perha Pharmaceuticals
Down Syndrome (DS), Down Syndrome (Trisomy 21)
Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation
The goal of this clinical trial is to learn if donanemab can reduce levels of amyloid in the brain, and if donanemab is safe and well-tolerated in participants with Down syndrome.
- Conditions
- Down Syndrome (DS), Down Syndrome (Trisomy 21), Alzheimer Disease, Amyloid Beta Protein
- Trial name
- ALADDIN (NCT06911944)
- Testing
- Donanemab
- Volunteers
- 60 people
- Sponsor
- Michael Rafii, MD, PhD
Down Syndrome, Alzheimer's Disease
Amyloid Plaque and Tangle Imaging in Alzheimer's Disease and Down Syndrome
The purpose of this study is to develop small molecule radio-labeled probes of beta-amyloid, to be used with positron emission tomography (PET) for early detection and treatment monitoring of Alzheimer disease (AD).
- Trial name
- NCT00965835
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Alzheimer's Disease, Mild Cognitive Impairment
Retinal Imaging in Neurodegenerative Disease
This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography (OCT) and OCT angiography (OCTA) as well as ultra-widefield (UWF) fundus photography to assess the structure and function of the…
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, Multiple Sclerosis
- Trial name
- NCT03233646
- Testing
- Retinal and Choroidal Imaging
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Duke University
Down Syndrome, Alzheimer's Disease
Glucose Metabolic, Amyloid, and Tau Brain Imaging in Down Syndrome and Dementia
The purpose of this study is to develop small molecule radio-labeled probes of beta-amyloid, to be used with positron emission tomography (PET) for early detection and treatment monitoring of Alzheimer disease (AD).
- Trial name
- NCT00966017
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)